Sensydia

Sensydia is a private medical device company developing a novel, non-invasive diagnostic platform called the Cardiac Performance System (CPS). The CPS uses proprietary sensors and machine learning algorithms to measure critical hemodynamic parameters like ejection fraction, cardiac output, and pulmonary artery pressure without invasive catheters. Its technology aims to transform point-of-care cardiac assessment in hospitals and clinics by providing rapid, accurate data to guide treatment for heart failure and critical care patients, potentially reducing costs and readmissions. The company has an FDA clearance for Ejection Fraction measurement and is advancing its pipeline for additional indications.

The Cardiac Performance System (CPS) is a non-invasive, automated platform that uses disposable sensors and proprietary machine learning algorithms to measure key hemodynamic parameters like Ejection Fraction, Cardiac Output, and Pulmonary Artery Pressure.

Sensydia competes with invasive gold-standard methods (Swan-Ganz catheters, thermodilution) and non-invasive alternatives like echocardiography for EF, and other minimally invasive or non-invasive cardiac output monitors (e.g., Edwards Lifesciences' ClearSight, Cheetah Medical's NICOM). Its unique proposed combination of multiple key parameters on one simple platform is its primary differentiator.